Cytori’s Celution One system, intended for hospitals as a platform device with life-critical applications across multiple specialties, has been granted the CE Mark.
Celution One is the next-generation device of the company’s Celution platform, which is a GMP-compliant technology that extracts and concentrates a patient’s own stem and progenitor cells from adipose at the point of care.
Celution One is designed to improve cell yield, processing volumes and processing times, and the versatility and efficiency of potential treatments.
Cytori CEO Christopher Calhoun said it is using the Celution One in pivotal heart attack trial ADVANCE, and aim of expand market access through broader indications for use and subsequent reimbursement applications.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData